UNSPSC 51283211: Fidaxomicin

This classification denotes a macrolide antibiotic with the molecular formula C52H74Cl2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5N076G8YQ, chemically known as [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl]3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate but generally known as Fidaxomicin, which bears US NIH Compound Identifier 10034073.

UNSPSC 51283211 Fidaxomicin, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The recent opportunities classified under this code — naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals through cooperative purchasing (Minnesota MMCAP) — involve naloxone, emergency medical supplies, and general pharmaceutical procurement, not the antibiotic fidaxomicin specifically. The code shows little relevant recent activity matching its nominal pharmaceutical scope, and the opportunities present reflect broader medical supply, emergency response, and pharmacy benefit management procurement rather than a targeted antibiotic line item.

The issuing bodies across these misaligned opportunities span county health departments, state health and human services agencies, municipal fire departments, and multi-state cooperative purchasing organizations. Geographic activity includes Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative. Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies estimated at $700,000 with a small business local enterprise set-aside (due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (due March 26, 2026). None of these opportunities specifically targets fidaxomicin procurement, suggesting either a code-tagging error in state and local systems or minimal current market activity for this specific antibiotic at the state and local level.